Business Wire

Aqara Announces Global Availability of Smart Lock U200

9.7.2024 10:00:00 EEST | Business Wire | Press release

Share

Aqara, a global leader and pioneer in IoT, today announced the official launch of the highly anticipated Smart Lock U200. Designed as a retrofit, keyless solution for home access management, the U200 lock offers unparalleled convenience, advanced security features, and seamless interoperability across smart home ecosystems and devices thanks to its native Matter compatibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709404547/en/

Aqara Smart Lock U200 (Photo: Business Wire)

The Aqara Smart Lock U200 brings a modern keyless lifestyle to a broad array of homeowners and renters, and provides multiple secure door entry options, including Apple home keys, which allow iOS users to unlock effortlessly by tapping a compatible iPhone or Apple Watch. The U200 distinguishes itself as one of the first Matter-over-Thread locks to support home key unlocking and is also one of the first retrofit smart locks to feature Apple home key.

Other unlocking methods of the Smart Lock U200 include:

  • Fingerprint recognition: Fast and secure access with the high-precision fingerprint reader.
  • PIN codes: Personalized codes can be entered on the included, pre-paired wireless keypad. Moreover, Aqara Home users can manage guess access easily with not only periodic passwords but also one-time passwords that can be remotely created, shared, and used even when the lock is disconnected from any platforms.
  • Mobile apps and voice assistants: Remote control via Aqara Home, Alexa, Apple Home/Siri, Google Home/Google Assistant, SmartThings, Home Assistant, and more1.
  • Aqara NFC cards: Quick and easy unlocking using Aqara’s NFC key fobs2.
  • Traditional keys: emergency access with the original keys.

The U200 lock stands out with its hassle-free retrofit design, allowing homeowners and renters to upgrade their existing locks - such as Euro mortise locks and US deadbolt locks - without the need to change keys or modify the door structure. This lock provides an instant smart update to most homes and is suitable for DIY installation, as attaching the U200 over the existing lock is simple and requires no tool apart from a screwdriver.

Security is a top priority with the Smart Lock U200. It features advanced encryption to protect against hacking, a tamper alarm on the wireless keypad, and an auto-lock function that secures the door automatically after a set period. Additionally, the U200 provides real-time notifications to keep users informed about their home’s security status.

The U200 retains many popular features of the previous Aqara locks, such as local and encrypted storage of sensitive data like fingerprints and passwords, anti-peep PIN code protection, Do-Not-Disturb mode, Passage mode, and Night Latch mode3. Furthermore, it adds thoughtful features like quiet unlock mode to minimize the noise level, pull spring feature for handle-less or inward-opening doors, as well as turn-to-lock and turn-to-unlock functions.

Built upon the energy-efficient Thread protocol, the U200 lock is designed for extended use. The lock runs on rechargeable Li-Ion batteries and boasts a battery life of up to 6 months between each charge. Additionally, the IPX5-rated wireless keypad is operable with AAA batteries or existing doorbell wiring, which allows for uninterrupted usage4.

The Smart Lock U200 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada) and Europe (France, Germany, Italy, Netherlands, Poland, Spain, UK), as well as through select Aqara retailers worldwide.

The U200 lock is compatible with Euro mortise locks with Emergency Function, and supports various cylinders including EU profile cylinders, select Scandi profile cylinders and UK oval cylinders. An Emergency Function enables the cylinder to be unlocked from the outside using a key, even if another key is already inserted on the inside. Adjustable cylinders are sold separately by Aqara. The U200 is also compatible with single-cylinder deadbolt locks.

For more information on the U200 lock and its compatibility, please visit our website.

  1. A Matter controller with Thread Border Router functionality is required to connect the Smart Lock U200 to any third-party Matter-enabled system.
  2. Aqara NFC card is available in-box with the Smart Lock U200 Kit or sold separately.
  3. Some of these features may not be available at the time of launch, and will be added via subsequent OTA updates.
  4. The 6-month battery life is based on the assumption of 8 cycles of unlocking and locking per day. To operate the wireless keypad with the existing doorbell wiring, a 12V-24V AC/DC power supply is required.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709404547/en/

Contacts

For Media Inquiries:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye